PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30508725-0	2019	Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats.	Pioglitazone	42-54	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	29-34	
30508725-4	2019	The aim of the present study was to evaluate whether PPARG activation (using the synthetic ligand pioglitazone (PGZ)) ameliorates the alterations in early ovarian function induced by androgen excess.	Pioglitazone	98-110	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	53-58	
30508725-4	2019	The aim of the present study was to evaluate whether PPARG activation (using the synthetic ligand pioglitazone (PGZ)) ameliorates the alterations in early ovarian function induced by androgen excess.	Pioglitazone	112-115	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	53-58	
30508725-7	2019	RESULTS: PGZ prevented the inactivation of ovarian PPARG induced by androgen excess by increasing PPARG itself and the gene expression of PPARG-coactivator 1 alpha (PGC1A), and by decreasing the gene expression of nuclear co-repressor (NCOR).	Pioglitazone	9-12	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	51-56	
30508725-7	2019	RESULTS: PGZ prevented the inactivation of ovarian PPARG induced by androgen excess by increasing PPARG itself and the gene expression of PPARG-coactivator 1 alpha (PGC1A), and by decreasing the gene expression of nuclear co-repressor (NCOR).	Pioglitazone	9-12	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	98-103